TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
GNI Group ( (JP:2160) ) has issued an update.
GNI Group Ltd. announced that its subsidiary, Gyre Therapeutics, has acquired additional shares in Gyre Pharmaceuticals, increasing its equity interest to 69.72%. This strategic move aims to minimize profit outflows to minority shareholders and enhance the Group’s corporate value, particularly as Gyre Pharmaceuticals is set to handle the entire value chain for a new liver fibrosis drug candidate. The acquisition is expected to positively impact the Group’s financial results, although the exact effect is still under review.
The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on developing and commercializing innovative drugs. Its primary products include treatments for liver fibrosis and other chronic conditions, with a market focus on expanding its equity interests and maximizing corporate value.
Average Trading Volume: 2,181,193
Technical Sentiment Signal: Buy
Current Market Cap: Yen147.7B
Find detailed analytics on 2160 stock on TipRanks’ Stock Analysis page.